Asunto(s)
Adenocarcinoma/terapia , Angioplastia/métodos , Neoplasias Duodenales/terapia , Arteria Hepática/anomalías , Pancreaticoduodenectomía/métodos , Vena Porta/cirugía , Adenocarcinoma/diagnóstico , Adenocarcinoma/patología , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Quimioterapia Adyuvante , Neoplasias Duodenales/diagnóstico , Neoplasias Duodenales/patología , Duodeno/irrigación sanguínea , Duodeno/patología , Duodeno/cirugía , Endoscopía del Sistema Digestivo , Femenino , Fluorouracilo/uso terapéutico , Arteria Hepática/diagnóstico por imagen , Arteria Hepática/cirugía , Humanos , Leucovorina/uso terapéutico , Arteria Mesentérica Superior/trasplante , Microcirugia/métodos , Invasividad Neoplásica , Compuestos Organoplatinos/uso terapéutico , Vena Porta/diagnóstico por imagen , Vena Porta/patología , Tomografía Computarizada por Tomografía de Emisión de Positrones , Resultado del Tratamiento , Ultrasonografía DopplerRESUMEN
OBJECTIVE: The objective was to examine the relationship between pre-, peri-, and postoperative specialized nutritional support with immune-modulating nutrients and postoperative morbidity in patients undergoing elective surgery. METHODS: Studies were identified by searching MEDLINE, review article bibliographies, and abstracts and proceedings of scientific meetings. All randomized clinical trials in which patients were supplemented by the IMPACT formula before and/or after elective surgery and the clinical outcomes reported were included in the meta-analysis. Seventeen studies (n=2,305), 14 published (n=2,102), and 3 unpublished (n=203), fulfilled the inclusion criteria. Ten studies (n=1,392) examined the efficacy of pre- or perioperative IMPACT supplementation in patients undergoing elective surgery, whereas 7 (n=913) assessed postoperative efficacy. Fourteen of the studies (n=2,083) involved gastrointestinal (GI) surgical patients. Postoperative complications, mortality, and length of stay in hospital (LOS) were major outcomes of interest. RESULTS: IMPACT supplementation, in general, was associated with significant (39%-61%) reductions in postoperative infectious complications and a significant decrease in LOS in hospital by an average of 2 days. The greatest improvement in postoperative outcomes was observed in patients receiving specialized nutrition support as part of their preoperative treatment. In GI surgical patients, anastomotic leaks were 46% less prevalent when IMPACT supplementation was part of the preoperative treatment. CONCLUSION: This study identifies a dosage (0.5-1 l/day) and duration (supplementation for 5-7 days before surgery) of IMPACT that contributes to improved outcomes of morbidity in elective surgery patients, particularly those undergoing GI surgical procedures. The cost effectiveness of such practice is supported by recent health economic analysis. Findings suggest preoperative IMPACT use for the prophylaxis of postoperative complications in elective surgical patients.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Suplementos Dietéticos , Nutrición Enteral/métodos , Infecciones/etiología , Complicaciones Posoperatorias/prevención & control , Relación Dosis-Respuesta a Droga , Procedimientos Quirúrgicos Electivos , Alimentos Formulados , Humanos , Tiempo de Internación , Atención Perioperativa , Complicaciones Posoperatorias/etiología , Cuidados PreoperatoriosRESUMEN
BACKGROUND: Potentially resectable periampullary tumours may not be treated appropriately due to lack of local expertise in both assessment of resectability and resection in referring centres. Tata Memorial Hospital is a major referral centre for oncology and these patients are finally referred to this institution. In carefully selected patients, resection can be accomplished. The purpose of the present paper was to determine the perioperative morbidity and mortality for patients undergoing reoperative pancreaticoduodenectomy at a major comprehensive cancer centre. METHODS: Between January 1991 and December 2001 15 patients, who had undergone previous non-resectional surgery for operable periampullary carcinoma, underwent re-exploration. The perioperative morbidity and mortality were analysed and compared with that of the group of patients undergoing primary pancreaticoduodenectomy (143 patients) in the same period. RESULTS: All the 15 patients undergoing re-exploration had a successful resection by pancreaticoduodenectomy. In the reoperative group eight patients (53%) underwent classic pancreaticoduodenectomy and seven patients (46%) had a pylorus-preserving pancreaticoduodenectomy, as compared to 102 (71%) and 41 (29%) patients in the primary surgery group, respectively. Although the mean operative time and the estimated blood loss were higher in the reoperative group, the morbidity and mortality rates were similar in the two groups. The overall 30-day mortality rate was 6.6% and 6.9% in the reoperative and the primary surgery group, respectively. Major morbidity occurred in two of the 15 patients (13.3%), and one patient (6.6%) died following surgery in the reoperative group. CONCLUSION: Reoperative pancreaticoduodenectomy can be performed safely in carefully selected patients with resectable, localized periampullary tumours with similar morbidity and mortality to patients undergoing primary surgery.